Financial News

AbbVie's patent cliff is already a thing of the past with Skyrizi and Rinvoq outperforming and other assets also strong. Dividends are safe, growth is back.

AbbVie turns a corner; patent cliff fears were overblown

February 02, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –

Topics Intellectual Property

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

January 29, 2024

Via Get News

January 29, 2024

AbbVie Inc. (NYSE: ABBV) Records 52-Week High Wednesday Morning

January 24, 2024

AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action

January 02, 2024

New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug...

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

January 29, 2024

Via TheNewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

January 04, 2024

December 26, 2023

AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action

December 22, 2023

While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend.

AbbVie continues shopping spree with biotech buyout

December 12, 2023

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.

December 11, 2023

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)

December 04, 2023

No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet.

Doing Your Holiday Shopping? These Stocks Might Make Great Gifts

December 04, 2023

A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.

Topics Bonds

These biotechs targeting multiple neurodegenerative diseases

December 01, 2023

AbbVie Inc. (NYSE: ABBV) Highlighted for Surprising Price Action

October 30, 2023

The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains.

These are the top sectors for blue chip growth in 2024

November 29, 2023

J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown

Topics Economy Intellectual Property

J&J, Gilead, BMS: A look at undervalued dividend payers

November 29, 2023

Guidance is a driving force for equity markets and can lead stock prices higher or lower, catalyze significant moves, and alter analysts' outlook

Guidance leads the market for these stocks; 1 raises, 1 lowers

November 07, 2023

The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector

Investor patience tested as pharmaceutical stocks take a tumble

November 01, 2023

Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements.

J&J stock down as business unit mulls talc-related bankruptcy

October 31, 2023

AbbVie's deep value and high yield attract income investors, and the patent cliff worry lessens daily.

Topics Bankruptcy Lawsuit

High-yield, deep-value AbbVie fell off the patent cliff and lived

October 27, 2023

The Clorox Company's 44% two-year plunge has created an opportunity to own a defensive stock with a shiny 3.6% dividend.

Topics Intellectual Property

Clorox Pullback Presents a Chance to Clean Up on a 3.6% Dividend

September 26, 2023

Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing

October 23, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

Flee to Healthcare Stocks if Recession Rears its Head?

September 20, 2023

EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END

Topics Economy

The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis

September 19, 2023

Via FinancialNewsMedia

Topics Economy

High Yield, Low Beta Stocks to Buy for the Next Market Meltdown

September 12, 2023

The market is set up for a fall, and it may start soon, as soon as the CPI data is released. These low-beta stocks are poised to outperform and pay dividends

Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease

Topics Economy Stocks

September 07, 2023

Data readout expected in Q4 2024

From Alector, Inc.

Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand.

A Significant Reversal is in Sight for These 5 Med Tech Companies

August 30, 2023